VA-MARS,-INCORPORATED
3.5.2024 15:01:32 CEST | Business Wire | Press release
Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland. With approximately 140 Associates, Cerba Vet provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
Headquartered in Lyon, France, ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests globally for diagnosing diseases in pets, as well as supporting scientific initiatives to preserve biodiversity.
Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.
Nefertiti Greene, President, Mars Science & Diagnostics, said: “We are excited about this opportunity and look forward to finalizing discussions and working together with the Cerba Vet and ANTAGENE teams to enhance our reach and drive R&D to help veterinarians improve animal health outcomes, delivering A BETTER WORLD FOR PETS™.”
Emmanuel Ligner, CEO, Cerba HealthCare, added: “We are proud of what the teams have accomplished over the years to lead innovation and enhance services for the entire veterinarian community. We believe that Mars Science & Diagnostics is the right investor for Cerba Vet and ANTAGENE and would be able to support the long-term development and growth of these businesses. Mars Science & Diagnostics is known for its commitment to science and innovation, strong partnerships with veterinary professionals and purpose-driven culture.”
The contemplated acquisition remains subject to the information and/or consultation of the employees and employee representative bodies of Cerba Vet and ANTAGENE. Completion of such contemplated acquisition would also be subject to customary closing requirements following the execution of definitive transaction agreements.
About Mars, Incorporated
For more than a century, Mars, Incorporated has been driven by the belief that the world we want tomorrow starts with how we do business today. This common purpose unites our 140,000+ Associates. It is at the center of who we are as a global, family-owned business, and it fuels how we are transforming, innovating, and evolving to make a positive impact on the world.
Every year, our diverse and expanding portfolio of quality confectionery, food, and pet care products and services delights millions of people and supports millions of pets. With more than $47 billion in annual sales, we produce some of the world’s best-loved brands including CESAR®, Ben’s Original™, PEDIGREE®, ROYAL CANIN®, Cocoavia®, DOVE®, EXTRA®, KIND®, M&M’s®, SNICKERS® and WHISKAS®. We are creating a better world for pets through nutrition, breakthrough programs in diagnostics, wearable health monitoring, DNA testing, pet welfare and comprehensive veterinary care with AniCura, BANFIELD™, BLUEPEARL™, Linnaeus and VCA™. Mars Science & Diagnostics is a division of Mars Petcare dedicated to one purpose: A BETTER WORLD FOR PETS. Science & Diagnostics brings together the power of leading science with expertise across diagnostics, data, and technology to change outcomes in pet health.
We know we can only be truly successful if our partners and the communities in which we operate prosper as well. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire our Associates to take action every day to help create a world tomorrow in which the planet, its people and pets can thrive.
For more information about Mars, please visit www.mars.com. Join us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
About Mars Science & Diagnostics
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business Antech spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90 reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503904264/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 08:00:00 CET | Press release
Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting20.3.2026 06:55:00 CET | Press release
The Board of Directors proposes a dividend of 0.35 CHF per registered share Harry Kirsch proposed as new independent member of the Board of Directors Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board members from L’Oréal Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST. Dividend proposal The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contributions and, in accordance with applicable tax regulations, will be free from Swiss withholding tax. Proposed elections to the Board of Directors of Galderma Group AG As previously announced, and in connection with L’Oréal’s increased investment in Galderma, the Board members representi
Andersen Consulting tilføjer samarbejdspartneren Milestone Technologies19.3.2026 19:02:00 CET | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sin platform for digital transformation med tilføjelsen af samarbejdspartneren Milestone Technologies, der er en veletableret global leverandør af it-services og digitale løsninger med base i USA. Milestone Technologies blev grundlagt i 1997 og leverer omfattende teknologi- og outsourcingløsninger, der spænder over digitale arbejdspladstjenester, cloud- og infrastrukturstyring, data, AI og automatisering, apps og digital engineering, business process outsourcing samt implementering af platforme som ServiceNow og Salesforce. Med hovedkontor i Fremont, Californien, opererer Milestone i 35 lande på globalt plan og samarbejder med nogle af verdens største virksomheder. Virksomhedens integrerede leveringsmodel gør det muligt for kunder at transformere deres it-drift, øge serviceeffektiviteten og skalere teknologiske økosystemer gnidningsfrit over hele verden. "Milestone Technologies er en medarbejderfokuseret organisation, der leverer målbare for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom